Tandem Diabetes Care Reports Q2 2026 Sales of $254.6M, Gross Margin Improves to 57%, Reaffirms Full-Year Guidance
TNDM sits 79% above its 52-week low of $9.98.
Summary
Tandem Diabetes Care reported Q2 2026 sales of $254.6 million, a 6% increase, with gross margin improving to 57%. The company reaffirmed its full-year 2026 guidance and highlighted key regulatory and product milestones, including a 510(k) submission for Tandem Mobi tubeless capability.
Key Events · Earnings and Guidance · TNDM
-
Q2 2026 Financial Results
Worldwide sales rose 6% to $254.6 million, with U.S. sales up 5% to $179.3 million and international sales up 7% to $75.3 million. Gross margin expanded 460 basis points to 57%, and GAAP operating loss narrowed to $13.8 million from $51.8 million a year ago.
-
Full-Year 2026 Guidance Reaffirmed
The company reaffirmed its 2026 sales guidance of $1.065 billion to $1.085 billion, gross margin of 56% to 57%, and adjusted EBITDA margin of 5% to 6%. Non-cash charge guidance was reduced from $100 million to $85 million.
-
Strategic and Regulatory Milestones
Submitted a 510(k) to the FDA for Tandem Mobi tubeless capability. Received FDA clearance and CE Mark for Control-IQ+ use in pregnancy, and CE Mark for type 2 diabetes. Launched Dexcom G7 15-day sensor compatibility and Abbott FreeStyle Libre 3 Plus sensor in Europe. Began international rollout of Tandem Mobi.
-
Improved Profitability Trajectory
Adjusted EBITDA turned positive at $6.4 million (3% of sales) compared to negative $1.8 million a year ago. The reduction in expected non-cash charges for 2026 signals lower stock-based compensation and depreciation, improving the path to GAAP profitability.
Analysis · TNDM · Industrial Applications And Services
Tandem Diabetes Care delivered a solid quarter with 6% sales growth and a 460-basis-point gross margin expansion to 57%, driving a significantly narrower operating loss. The company reaffirmed its full-year 2026 guidance, signaling confidence in its commercial strategy and product pipeline. The submission of a 510(k) for the Tandem Mobi tubeless capability and multiple regulatory clearances expand the addressable market and strengthen the competitive position. The reduction in expected non-cash charges improves the earnings outlook. This earnings report provides a positive update on the company's turnaround, with improving profitability and strategic milestones that support the investment thesis.
At the time of this filing, TNDM was trading at $17.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.98 to $29.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.